To assess safety and efficacy of propofol and thiopental for refractory status epilepticus (RSE) in children, the authors reviewed 34 episodes of RSE. Thiopental was effective in most patients, but there were serious side effects. Propofol was used according to a strict protocol. It was effective in most patients, so that thiopental was not needed. Side effects were infrequent, of minor severity, and fully reversible. The authors suggest the use of propofol before thiopental.
Thiopental is commonly used as a last treatment in refractory status epilepticus (RSE). 1 Side effects of thiopental are well described, but little is known about their frequency and impact on clinical practice. Because of the adverse effects of thiopental, several guidelines recommend propofol as an alternative therapy before thiopental. However, propofol is associated with potentially fatal outcome, 2,3 and its efficacy in the treatment of RSE is mainly based on case reports and small case series.
To assess safety and efficacy of propofol and thiopental in the treatment of RSE in children, we reviewed all patients treated with these drugs in our department.
Methods. Between January 1993 and 2004, 33 patients were treated for 34 episodes of RSE in the intensive care unit (ICU) of the Wilhelmina Children's Hospital, the Netherlands. Patient 12 was admitted twice; during his first admission RSE was terminated with propofol. During the second admission, 5 months later, thiopental was necessary.
RSE was defined as continuous seizure activity clinically and on EEG, which failed to respond to phenytoin and high doses of midazolam (0.5 to 1.0 mg/kg/hour), and persisted for more than 60 minutes. RSE was generalized or multifocal in 29 patients and focal in 5. Focal RSE had persisted for several days before propofol or thiopental was started and was accompanied by serious discomfort.
Before 1999, patients with RSE were primarily treated with thiopental. After 1999, propofol was administered systematically to all children before thiopental was started, reserving thiopental for those who had side effects with propofol or did not respond to it.
When propofol was used, a bolus of 1 to 2 mg/kg was given, followed by continuous infusion of 1 to 2 mg/kg/hour. If necessary, maintenance infusion was increased to a maximum of 5 mg/kg/hour. Side effects were regularly monitored, and infusion was stopped if side effects emerged. The goal of treatment with propofol was disappearance of clinical seizures and epileptic activity on the EEG.
Thiopental was started according to a dosing scheme made by the pharmacy department, based on pharmacokinetic data of previously treated patients. A loading dose was given, aiming at a blood level of 20 mg/mL after 6 hours. This was followed by continuous infusion, which was adjusted when necessary according to the EEG. The goal of treatment with thiopental was complete control of seizures with a burst suppression pattern on the EEG.
In patients treated with propofol, special attention was paid to blood levels of lactate, triglycerides, creatine kinase, and blood gas analyses. In patients treated with thiopental, special attention was paid to respiratory, circulatory, and infectious complications.
Short-term seizure control was assessed at discharge from the ICU and classified as complete seizure freedom (SF), decrease of seizure frequency (DSF), or continuing status epilepticus (CSE). At discharge from hospital, short-term neurologic outcome was assessed and classified as returned to baseline (RTB), progressive deterioration (PD), or death (D). 4
Results. Effects of propofol and thiopental on seizure activity and short-term neurologic outcome are summarized in the figure. Tables E-1 and E-2 (on the Neurology Web site at www.neurology.org) contain clinical characteristics of included patients.
Propofol. Propofol was used in 22 episodes of RSE. All children had a convulsive status epilepticus. Mean duration of treatment with propofol was 57 hours (range 10 to 264 hours). Propofol had to be stopped on four occasions (18%) because of side effects: one patient had rhabdomyolysis (Patient 8) and three patients developed hypertriglyceridemia (Patients 13, 17, 18). The elevation of triglycerides and creatine kinase normalized quickly after propofol was stopped. In Patients 17 and 18, RSE was not terminated when propofol was stopped because of side effects. Both patients were treated with thiopental afterwards.
In 14 of the 22 episodes treated with propofol (64%), RSE could be adequately controlled. Two patients who were successfully treated with propofol died. Their death was attributed to severe neurologic damage after bacterial meningitis, and not related to the use of propofol.
Thiopental. Twenty patients were treated with thiopental. Nineteen had a convulsive status epilepticus. One child (Patient 23) received muscle relaxants, when an EEG Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the August 23 issue to find the title link for this article. showed status epilepticus. Clinical signs of convulsions could obviously not be assessed. Mean duration of thiopental infusion was 8.6 days (range 2 to 33 days).
Seizure control with thiopental was achieved in 11 out of 20 children (55%). In 6 of the children who died, death was related to the underlying disorder and could not be avoided despite treatment. In 2 patients, thiopental probably contributed to their deaths: Patient 21 died of acute hepatic failure induced by thiopental, Patient 30 died of progressive pulmonary damage during thiopental infusion.
All children required extra fluids and inotropes. With these measures, circulation was adequate in all but one child (Patient 16). She developed multiple organ dysfunction syndrome with acute tubular necrosis, for which peritoneal dialysis was necessary. After thiopental was stopped, she had complete recovery of organ functions.
All children required mechanical ventilation. Fifteen children (75%) developed infiltrates on their chest X-rays, and required higher airway pressures and supplemental oxygen during thiopental infusion. Eleven patients (55%) developed pleural effusions. Patient 30 died due to progressive pulmonary abnormalities, while all other children had a complete recovery of their respiratory status.
Eighteen children (90%) were treated with antibiotics during thiopental coma, mostly because of fever and suspected pneumonia. Sputum cultures, however, were positive in only 33% of patients. Three children had a sepsis from their central lines during ICU admission.
Discussion. We found that propofol is a safe, effective drug in the treatment of pediatric RSE. With propofol, treatment with thiopental could be prevented in a considerable subgroup of patients.
Our study is the first that assesses safety and efficacy of propofol and thiopental in the treatment of RSE in children. Compared to other studies, the number of patients included is relatively high. However, it is a retrospective study and randomization between the two treatment strategies did not take place: patients were either treated with thiopental (before 1999) or with propofol followed by thiopental when necessary (after 1999) . With this study it is therefore not possible to compare safety and efficacy of propofol and thiopental.
There are several advantages in using propofol: effective seizure suppression can be achieved in most patients. 5, 6 Since it is a very fast acting drug, quicker seizure control can be obtained with propofol than with thiopental. 5 Even if propofol fails to terminate RSE, little time is lost.
The main concern with respect to propofol is in its potentially fatal side effects. 2, 3 However, several studies reported that it is safe to use propofol, if the maximum dose during prolonged infusion does not exceed 5 mg/kg/hour 7, 8 and if infusion is stopped when side effects emerge. Studies that compared propofol vs barbiturates 5 or midazolam 6 found a higher mortality rate in patients treated with propofol, but dosages in those studies were far above 5 mg/ kg/hour. Only the minority of our patients had side effects, which were of limited severity and fully reversible. Mortality rate in children treated with propofol was low, supporting the conclusion that it is safe to use propofol under the aforementioned restrictions.
The findings in our patients confirm that hemodynamic problems during thiopental infusion can be adequately managed. 9, 10 The influence of thiopental on the respiratory tract was larger than expected. Most patients had suspected pneumonia, while other infections were not often encountered.
We recommend that before thiopental is started in children with RSE, treatment with propofol should be considered, with a dosage up to 5 mg/kg/hour, under strict observation of potential side effects. Figure. Effects of propofol and thiopental on seizure activity and short-term neurologic outcome. Short-term seizure control assessed at discharge from the intensive care unit: SF ϭ seizure free; DSF ϭ decrease of seizure frequency; CSE ϭ continuing status epilepticus; ND ϭ seizure control could not be determined because of progressive cerebral herniation or death during thiopental treatment. Shortterm neurologic outcome assessed at discharge from hospital: RTB ϭ returned to baseline; PD ϭ progressive deterioration; D ϭ death.
